Simple Summary Immune Checkpoint Inhibitors (ICIs) have demonstrated clinical efficacy in
Microsatellite Instability High Colorectal Cancer (MSI-H CRC). However, in Microsatellite …

Simple Summary Immune checkpoint inhibitors have revolutionized the treatment landscape
of microsatellite instable colorectal cancer. However, their efficacy is very limited in patients …

Opinion statement Advanced colorectal cancer (CRC) is a heterogeneous disease,
characterized by several subtypes with distinctive genetic and epigenetic patterns. During …

Simple Summary The majority of metastatic colorectal cancer cases are mismatch-repair-
proficient and microsatellite-stable, and unfortunately this condition is associated with an …

Simple Summary Microsatellite instability (MSI) is a molecular indicator of defective DNA
mismatch repair (dMMR). MSI/dMMR status is observed in approximately 5% of metastatic …

Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …

Simple Summary Immunotherapy has reshaped the prognosis of several tumor types. In
metastatic colorectal cancer, only tumors with microsatellite instability or mismatch repair …

Simple Summary The implementation of immunotherapy in the therapeutic landscape of
colorectal carcinoma has been difficult due to the inefficacy reported in early clinical trials …

With the development of immune checkpoint inhibitors, immunotherapy researchers have
facilitated substantial progress for patients with mismatch repair deficient/microsatellite …

Introduction: Colorectal cancer (CRC) is the third most common malignancy worldwide, with
recent trends demonstrating increasing incidence amongst younger patients. Despite …